Ensysce Biosciences Inc.

Ensysce Biosciences Inc. is a pharmaceutical company dedicated to discovering and developing innovative therapeutic solutions with a focus on addressing the opioid crisis. Its primary function is the development of safer, abuse-resistant prescription medications to manage pain effectively while reducing the risk of misuse and addiction. One of the company's notable features is its proprietary technology platforms, including the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to create opioid treatments with built-in safety mechanisms to minimize the potential for abuse and overdose. Ensysce’s work is particularly impactful in the healthcare and pharmaceutical sectors, where managing pain with minimal societal harm is a critical concern. By targeting significant health issues with its pioneering formulations, the company plays a vital role in transforming treatment paradigms and contributing to the creation of a safer, more effective pain management landscape in the financial market.